论文部分内容阅读
目的:探讨放射性核素~(131)I应用于甲亢治疗的安全性与有效性。方法:选择2013年8月到2016年2月选择在我院诊治的甲亢患者240例,根据随机信封抽签原则分为观察组与对照组各120例,对照组口服丙硫氧嘧啶片治疗,观察组在对照组治疗的基础上给予放射性核素~(131)I治疗,治疗观察3个月,记录治疗的安全性与有效性。结果:治疗后,观察组总有效率为96.7%,明显高于对照组的86.7%(P<0.05)。观察组治疗后血清甲状腺激素水平明显低于治疗前及对照组(P<0.05)。观察组治疗期间的甲减、粒细胞减少、肝脏损害、贫血等不良反应发生率为11.7%,对照组为10.8%,两组不良反应的发生率对比差异无统计学意义(P>0.05)。结论:放射性核素~(131)I可使甲亢患者的甲状腺激素的分泌和合成显著减少,安全性及有效性均较高。
Objective: To investigate the safety and effectiveness of radionuclide 131I applied in the treatment of hyperthyroidism. Methods: From August 2013 to February 2016, 240 patients with hyperthyroidism who were selected for treatment in our hospital were selected. According to random enumeration, 120 cases were divided into observation group and control group. The control group was treated with propylthiouracil tablets. The patients in the control group were treated with radionuclide ~ (131) I for 3 months. The safety and efficacy of the treatment were recorded. Results: After treatment, the total effective rate in the observation group was 96.7%, which was significantly higher than that in the control group (86.7%, P <0.05). The level of serum thyroid hormone in observation group after treatment was significantly lower than that before treatment and in control group (P <0.05). The incidence of adverse reactions such as hypothyroidism, neutropenia, liver damage and anemia was 11.7% in the observation group and 10.8% in the control group. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). CONCLUSION: Radionuclide 131I can significantly reduce thyroid hormone secretion and synthesis in patients with hyperthyroidism, with high safety and efficacy.